---
title: "Stereotaxis, Inc. 1Q 2026: Revenue $6.29M, EPS $(0.06) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286308157.md"
description: "Stereotaxis, Inc. reported Q1 2026 revenue of $6.29M, down 15.8% from $7.47M a year prior, with a net loss of $(6.17M) and diluted EPS of $(0.06). The decline was attributed to lower system sales and a transition to proprietary catheters. Despite this, the company achieved regulatory clearances for several products and announced the acquisition of Robocath to enhance its robotic portfolio. Operational risks remain due to supply-chain pressures and macroeconomic factors affecting production and costs."
datetime: "2026-05-13T19:51:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286308157.md)
  - [en](https://longbridge.com/en/news/286308157.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286308157.md)
---

# Stereotaxis, Inc. 1Q 2026: Revenue $6.29M, EPS $(0.06) — 10-Q Summary

Stereotaxis, Inc. reported first-quarter 2026 results with revenue of $6.29M, down from $7.47M a year earlier, and a net loss attributable to common stockholders of $(6.17M). Diluted loss per share was $(0.06) for the quarter.

**Financial Highlights**

-   Revenue was $6.29M for Q1 2026, down from $7.47M in the year-ago quarter ( (15.8%) ).
-   Net income: Net loss attributable to common stockholders $(6.17M) for Q1 2026, versus $(6.14M) in the year-ago quarter.
-   Diluted EPS was $(0.06) for Q1 2026, compared with $(0.07) in the year-ago quarter.

**Business Highlights**

-   Revenue decline of about 16% year-over-year was driven by lower system sales and the transition from J&J-supplied catheters to the company’s proprietary MAGiC disposable catheters, which caused a temporary reduction in disposable volumes.
-   Regulatory and product momentum continued with multiple clearances in 2025 through Q1 2026, including GenesisX, MAGiC, MAGiC Sweep and Synchrony, supporting ongoing commercialization efforts.
-   Strategic moves include the announced acquisition of Robocath to broaden the company’s robotic interventional portfolio and integration of APT for catheter manufacturing.
-   Operational risks persist from supply-chain pressures, tariffs and broader macroeconomic factors that have impacted production, costs and the timing of global system adoption.

Original SEC Filing: Stereotaxis, Inc. \[ STXS \] - 10-Q - May. 13, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [STXS.US](https://longbridge.com/en/quote/STXS.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [APT.US](https://longbridge.com/en/quote/APT.US.md)

## Related News & Research

- [University of Szeged Pioneers First Robotic Cardiology Program in Hungary | STXS Stock News](https://longbridge.com/en/news/293215157.md)
- [Tesla is Betting Robots Are The Next Nvidia. This Could Be the Biggest Shift Since the AI Boom.](https://longbridge.com/en/news/294224931.md)
- [Baxter Q2 2026 Earnings Preview](https://longbridge.com/en/news/294224876.md)
- [China's Unitree says "GPT moment" for robots remains years away](https://longbridge.com/en/news/293990253.md)
- [China warns of retaliation if US sticks with robot ban](https://longbridge.com/en/news/294286051.md)